Transcranial Pulse Stimulation (TPS) is an innovative treatment method for patients with Alzheimer's dementia. To better understand its application, obtain an overview of patient numbers and gain a clinical global impression of the treatment outcomes, we conduct annual surveys. In this year's survey, 35 centres participated. In this blog post, you can discover the latest findings and analyses from our recent TPS survey.
Number of patients with Alzheimer’s dementia treated with TPS
The calculations of the survey showed that in the past year alone (2023), the 35 surveyed centres treated 1 132 patients in over 16 352 sessions with TPS for Alzheimer's dementia. Overall, these centres have treated a total of 3 318 patients as of January 2024.
Number of sessions and pulses per session
Our survey found that more than 80% of treatments involve the recommended 6 000 pulses and six initial sessions. 91% of the centres conduct additional refresher sessions, usually scheduled at an average interval of four to eight weeks.
Energy levels used during treatments
The majority of centres, about 66%, use the recommended energy level of 0.25 mJ/mm², which is the maximum energy for TPS. 29% of the centres use 0.2 mJ/mm², and 5% use a variety of energy levels.
Clinical global impression of the outcomes and side effects
In line with published clinical studies on TPS, our survey revealed that many centres reported improvements in their clinical global impression of patient outcomes. Specifically, 39% of centres noted slight improvements, and another 39% observed significant improvements. Around 16% of the centres reported that their patients' conditions remained stable, while only one centre reported any deterioration.
Regarding side effects, the majority of centres (85%) did not observe any. When side effects did occur, they were typically well-tolerated, mild in form, and subsided within a few hours. The side effects stated were headaches, dizziness, and fatigue.
The 2024 TPS survey provides valuable clinical insights into the use of TPS and we are looking forward to next year’s survey.
Learn more about Transcranial Pulse Stimulation (TPS) with the NEUROLITH® as an add-on treatment option for patients with Alzheimer's disease.